JRP Bio
AboutPipelinesBusinessPressContact
KOEN
Workspace
JRP Bio

Where botanicals meet evidence

JRP Bio standardizes traditional Korean medicine formulas and natural products, builds the evidence behind them, and secures regulatory approval to turn them into products people actually use.

JRP Bio is the business brand of Jaein R&P Co., Ltd.
Room 304, Global Center, Seoul Bio Hub, 117-3 Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea

KOEN

Sitemap

  • About
  • Pipelines
  • Business
  • Press
  • Contact

Contact

  • bs@jrpbio.com
  • +82-2-6925-5568
  • Employee workspace
© 2026 Jaein R&P Co., Ltd. · All rights reserved.

Press

Press releases


Research, regulatory and business news from JRP Bio.

2026.09Company

JRP Bio to open Jecheon Production Center in October

A base for producing its standardized botanical ingredients — the first production infrastructure for the Natural Products Foundry

Read release→
  • 2026.03Intellectual property

    JRP Bio granted Korean patent for immune-enhancing use of SH003

    “Composition for enhancing immunity comprising a mixed herbal extract,” Korean Patent No. 10-2940993

    →
  • 2025.08Clinical · regulatory

    JRP Bio receives phase 2a IND approval for SH003 with docetaxel in NSCLC

    Moving to efficacy after three monotherapy and combination phase 1 trials

    →
  • 2025.01Clinical · regulatory

    JRP Bio completes human study of SH003 on immune function

    Randomized, double-blind, placebo-controlled design — registration as a functional ingredient under review

    →
  • 2024.05Partnership

    JRP Bio signs three-party MOU with Kwangdong Pharmaceutical and Kyung Hee University MRC

    Collaboration with Kwangdong's Natural Product Convergence R&D Division and the MRC for reinterpreting herbal medicine in cancer

    →
  • 2023.10Clinical · regulatory

    JRP Bio completes phase 1 trial of SH003 with docetaxel

    Third phase 1 trial after low-dose and high-dose monotherapy

    →
  • 2023.06Company

    JRP Bio selected for TIPS

    Selection for the private investment-led tech startup program accelerates botanical drug development

    →